<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC101583</article-id><article-id pub-id-type="pmcid-ver">PMC101583.1</article-id><article-id pub-id-type="pmcaid">101583</article-id><article-id pub-id-type="pmcaiid">101583</article-id><article-id pub-id-type="pmid">11036003</article-id><article-id pub-id-type="doi">10.1128/aac.44.11.2932-2938.2000</article-id><article-id pub-id-type="publisher-id">0368</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to <italic>Candida albicans</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Marchetti</surname><given-names initials="O">O.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Entenza</surname><given-names initials="JM">J. M.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanglard</surname><given-names initials="D">D.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bille</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Glauser</surname><given-names initials="MP">M. P.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moreillon</surname><given-names initials="P">P.</given-names></name><xref ref-type="aff" rid="N0x96b83c0.0x9b9d478">1</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib></contrib-group><aff id="N0x96b83c0.0x9b9d478"> Division of Infectious Diseases, Department of Internal Medicine,<sup>1</sup> and  Institute of Microbiology,<sup>2</sup> Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Phone: 41-21-314-10-26. Fax: 41-21-314-10-36. E-mail: <email>pmoreill@chuv.hospvd.ch</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2000</year></pub-date><volume>44</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">2787</issue-id><fpage>2932</fpage><lpage>2938</lpage><history><date date-type="received"><day>2</day><month>5</month><year>2000</year></date><date date-type="rev-request"><day>15</day><month>6</month><year>2000</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-29 05:27:25.643"><day>29</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac002932.pdf"/><abstract><p>Recent observations demonstrated that fluconazole plus cyclosporine (Cy) synergistically killed <italic>Candida albicans</italic> in vitro. This combination was tested in rats with <italic>C. albicans</italic> experimental endocarditis. The MICs of fluconazole and Cy for the test organism were 0.25 and &gt;10 mg/liter, respectively. Rats were treated for 5 days with either Cy, amphotericin B, fluconazole, or fluconazole-Cy. Although used at high doses, the peak concentrations of fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the kidneys. However, only the kidneys displayed concomitant polymorphonuclear infiltration. The therapeutic results reflected this dissociation. In the vegetations, only the fungicidal fluconazole-Cy combination significantly decreased fungal densities compared to all groups, including amphotericin B (<italic>P</italic> &lt; 0.0001). In the kidneys, all regimens except the Cy regimen were effective, but fluconazole-Cy remained superior to amphotericin B and fluconazole alone in sterilizing the organs (<italic>P</italic>&#8201;&lt;&#8201;0.0001). While the mechanism responsible for the fluconazole-Cy interaction is hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>